VaLiDate-R
Research type
Research Study
Full title
Can Very Low Dose Rivaroxaban (VLDR) in addition to dual antiplatelet therapy (DAPT) improve thrombotic status in acute coronary syndrome (ACS)
IRAS ID
246526
Contact name
Diana Gorog
Contact email
Sponsor organisation
East and North Hertfordshire NHS Trust
Eudract number
2018-003299-11
Duration of Study in the UK
3 years, 0 months, 1 days
Research summary
Heart attacks are caused by a blood clot occurring in a blood vessel (artery) which supplies blood to the heart. Such a clot can build up and block the blood flow, depriving part of the heart muscle of oxygen and blood, causing transient or permanent damage to the heart muscle.
The standard treatment for a heart attack is two blood thinning medications combined, every day, to reduce the risk of further blood clots forming and to prevent another heart attack.
The highest risk of another heart attack is in the next 30 days after the first heart attack.
However, despite two blood thinners combined, some patients still go on to have another clot (heart attack or stroke or death) and this can be life threatening.
Our earlier research has shown that through a blood test, we can identify patients who remain at increased risk of further clots and who may benefit from further blood thinners to reduce the risk of further heart attack, stroke and death in the next 30 days.
The aim of this study is to test which of 3 blood thinning treatment options (all already in widespread clinical use) is best for patients to reduce further blood clots, in particular the addition of low dose rivaroxaban.REC name
London - Hampstead Research Ethics Committee
REC reference
18/LO/1608
Date of REC Opinion
17 Oct 2018
REC opinion
Favourable Opinion